Medpace Holdings, Inc. (MEDP) Shareholders & Insider Trades
Medpace shareholders at a glance
The largest holder of Medpace stock is August Troendle18.51 %, with 5.2 million shares (18.51% of the company), worth about $3.07 billion as of September 25, 2026. The 10 largest holders together own 56.1%.
In Q2 2026, 716 institutional holdings reports listed shares worth $13.10 billion.
Insiders reported 74 transactions in the last two years: 29 sales worth $327.77 million and 1 purchase. The newest one on file is from April 24, 2026 (Brady Kevin M., Chief Financial Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through April 24, 2026.
Medpace Holdings, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Medpace shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| August Troendle18.51 % | 5.2 million | 18.51% | $3.1B |
| BlackRock Advisors LLC | 2.3 million | 8.42% | $1.4B |
| T. Rowe Price International Ltd. | 2.1 million | 7.42% | $1.2B |
| AQR Capital Management LLC | 1.3 million | 4.58% | $760.0M |
| Vanguard Portfolio Management LLC | 1.1 million | 4.06% | $673.0M |
| Vanguard Capital Management LLC | 1.0 million | 3.68% | $610.0M |
| State Street Corporation | 710,895 | 2.55% | $422.0M |
| Geode Capital Management LLC | 710,465 | 2.54% | $422.0M |
| Wasatch Advisors LP | 636,595 | 2.28% | $378.0M |
| Invesco Advisers, Inc. | 579,241 | 2.08% | $344.0M |
As of September 25, 2026.
Medpace institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 716 | – | $13.1B |
| Q1 2026 | 749 | 24.1 million | $11.6B |
| Q4 2025 | 806 | 23.9 million | $13.4B |
| Q3 2025 | 695 | 24.2 million | $12.4B |
| Q2 2025 | 623 | 26.8 million | $8.4B |
| Q1 2025 | 604 | 25.6 million | $7.8B |
| Q4 2024 | 607 | 25.4 million | $8.4B |
| Q3 2024 | 603 | 25.6 million | $8.6B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Medpace insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Brady Kevin M. | Apr 24, 2026 | Chief Financial Officer | Conversion of Exercise of derivative security at price 138.87 per share. | $972,090 |
| Ewald Stephen P | Apr 24, 2026 | General Counsel | Conversion of Exercise of derivative security at price 138.87 per share. | $486,045 |
| Kraft Robert O | Mar 31, 2026 | Director | -- | – |
| Carley Brian T | Mar 31, 2026 | Director | -- | – |
| Mccarthy Cornelius P. Iii | Mar 31, 2026 | Director | -- | – |
| Burwig Susan Elizabeth | Mar 18, 2026 | Officer | Conversion of Exercise of derivative security at price 166.73 per share. | $2.0M |
| Geiger Jesse J | Mar 17, 2026 | President | Conversion of Exercise of derivative security at price 138.87 per share. | $4.4M |
| Geiger Jesse J | Mar 17, 2026 | President | Sale at price 455.30 per share. | $14.4M |
| Ewald Stephen P | Feb 17, 2026 | General Counsel | Conversion of Exercise of derivative security at price 138.87 per share. | $486,045 |
| Carley Brian T | Feb 13, 2026 | Director | Conversion of Exercise of derivative security at price 54.99 per share. | $355,895 |
| Burwig Susan Elizabeth | Feb 13, 2026 | Officer | Conversion of Exercise of derivative security at price 107.93 per share. | $1.2M |
| Kraft Robert O | Dec 31, 2025 | Director | -- | – |
Newest 12 of 74 insider transactions in the last two years.
Questions and answers
Who owns the most Medpace stock?
August Troendle18.51 %, with 18.51% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (8.42%) and T. Rowe Price International Ltd. (7.42%).
How many institutions own Medpace stock?
716 institutional holdings reports listed Medpace shares in Q2 2026 worth $13.10 billion.
Are Medpace insiders buying or selling the stock?
In the last two years insiders reported 29 sales and 1 purchase (74 transactions in all); the newest on file is from April 24, 2026.
